ParticipantsNguyen Minh Duc, MD, Ho Chi Minh, Vietnam (Presenter) Nothing to Disclose
Rajiv Chopra, PhD, Dallas, TX (Abstract Co-Author) Stockholder, Profound Medical Corporation; Stockholder, Solenic Medical Inc
Bilgin Keserci, PhD, Kota Bharu, Malaysia (Abstract Co-Author) Nothing to Disclose
bsnguyenminhduc@pnt.edu.vn
PURPOSETo investigate the impact of oxytocin on high-intensity focused ultrasound (HIFU) ablation for the treatment of leiomyoma.
METHOD AND MATERIALSThis clinical trial study was approved by institutional review board. 40 patients with symptomatic leiomyoma underwent HIFU treatment. They were divided into two groups based on perfusion classification: group A (n = 20, if time-signal intensity curve of leiomyoma lower than that of myometrium regarded as weak perfusion group) and group B (n = 20, if time-signal intensity curve of leiomyoma equal to or higher than that of myometrium). Groups A and B was subdivided into two subgroups A1 (n = 10), B1 (n = 10) (with only intravenous infusion normal saline) considered as control group and two subgroups A2 (n = 10), B2 (n = 10) with intravenous infusion oxytocin 0.2 U/min (with 500 ml of 0.9% normal saline added 60 units of oxytocin running at the rate of 2 ml/min) considered as oxytocin group. Treatment results, adverse events were compared.
RESULTSThe mean non-perfused volume ratio (NPVr) of groups A and B was 92% ± 18 and 67% ± 24 (p<0.05). The mean power of groups A and B was 160W ± 28 and 200W ± 34 (p<0.05). The mean time treatment of groups A and B was 134minute ± 12 and 155minute ± 30 (p<0.05). The mean NPVr of subgroup A1 and A2 was 93% and 90% (p>0.05). The mean power of subgroups A1 and A2 was 158W and 164W (p>0.05). The mean treatment time of subgroup A1 and A2 was 126minute and 138minute (p>0.05). The mean NPVr of subgroup B1 and B2 was 72% and 60% (p<0.05). The mean power of subgroup B1 and B2 was 192W and 222W (p<0.05). The mean treatment time of subgroup B1 and B2 was 140minute and 168minute (p<0.05). There were no differences in adverse events between group A and group B, subgroups A1 and A2, B1 and B2. There were no oxytocin-related adverse events reported.
CONCLUSIONOxytocin could solely improve the treatment efficacy by reducing the power, enhancing the treatment speed, thus achievement of higher NPVr for patients with strong perfusion leiomyoma.
CLINICAL RELEVANCE/APPLICATIONThe clinicians should take oxytocin into consideration during ablation procedure in cases of strong perfusion leiomyoma to obtain better HIFU outcomes for patients.